Oxford BioDynamics Plc (AIM:OBD)

Oxford BioDynamics Cash Flow Statement

Financials in millions GBP. Fiscal year is October - September.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Net Income	-11.57	-10.83	-6.71	-6.68	-4.35
Depreciation & Amortization	1.41	1.32	1.18	1.05	0.43
Other Amortization	0.05	0.04	0.03	0.03	0.03
Loss (Gain) From Sale of Assets	-	0	0	-	-0
Asset Writedown & Restructuring Costs	0.9	-	-	-	-
Loss (Gain) on Equity Investments	-	-	-	-	0.04
Stock-Based Compensation	0.51	0.33	0.39	0.25	0.25
Other Operating Activities	-0.84	1.51	-1.07	-0.36	-0.03
Change in Accounts Receivable	-0.43	-0.45	0.47	-0.56	0.14
Change in Inventory	-0.05	0.06	0.06	-0.07	-0.08
Change in Accounts Payable	-0.17	-0.29	0.48	0.42	0.17
Operating Cash Flow	-10.17	-8.29	-5.18	-5.92	-3.4
Capital Expenditures	-0.08	-0.25	-0.36	-2.69	-0.11
Sale of Property, Plant & Equipment	-	-	-	-	0
Sale (Purchase) of Intangibles	-0.52	-0.47	-0.54	-0.4	-0.35
Investment in Securities	-1	0.03	2.14	3.22	4.91
Other Investing Activities	0.11	0.07	0.01	2.69	0.12
Investing Cash Flow	-1.49	-0.62	1.25	2.83	4.58
Long-Term Debt Repaid	-0.62	-0.72	-0.7	-0.69	-0.18
Net Debt Issued (Repaid)	-0.62	-0.72	-0.7	-0.69	-0.18
Issuance of Common Stock	9.86	15.39	3.62	-	-
Other Financing Activities	-0.98	-1.46	-0.36	-0.11	-
Financing Cash Flow	8.25	13.21	2.56	-0.8	-0.18
Foreign Exchange Rate Adjustments	-0.02	-0.02	0.16	-0.05	-0.08
Net Cash Flow	-3.42	4.28	-1.2	-3.94	0.92
Free Cash Flow	-10.25	-8.54	-5.54	-8.61	-3.51
Free Cash Flow Margin	-1611.95%	-1675.29%	-3597.40%	-2525.22%	-769.30%
Free Cash Flow Per Share	-0.04	-0.06	-0.06	-0.09	-0.04
Cash Interest Paid	0.23	0.21	0.2	0.11	-
Cash Income Tax Paid	-0.45	-0.81	-0.96	-0.59	-0.59
Levered Free Cash Flow	-8.22	-4.66	-3.7	-6.98	-2.74
Unlevered Free Cash Flow	-8.08	-4.53	-3.58	-6.91	-2.73
Change in Net Working Capital	1.97	-0.86	-1.09	0.46	-0.1

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.